Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Ligand Pharmaceuticals Inc.    LGND

LIGAND PHARMACEUTICALS INC. (LGND)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Ligand Pharmaceuticals : , Janssen Enter R&D Deal

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/11/2018 | 11:34pm CEST
   Micah Maidenberg 
 

Subsidiaries of Ligand Pharmaceutical Inc. (LGND) and Johnson & Johnson have entered into a research-and-development agreement focused on a "transgenic chicken platform" aimed at generating and discovering antibodies for humans, according to a securities filing.

Ligand's company Crystal Bioscience Inc., and Janssen Research & Development LLC, which is part of the Janssen Pharmaceutical Cos. of Johnson & Johnson, agreed to work together on Ligand's development of the platform, the filing said.

Under the deal, Ligand will be able to earn milestone payments contingent on various deliverables and will be able to sell the platform to others in the market.

Write to Micah Maidenberg at [email protected]

Stocks mentioned in the article
ChangeLast1st jan.
JOHNSON & JOHNSON -1.01% 127.8 Delayed Quote.-10.76%
LIGAND PHARMACEUTICALS INC. 2.25% 226.73 Delayed Quote.61.94%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on LIGAND PHARMACEUTICALS INC
07/11LIGAND PHARMACEUTICALS : Janssen Enter R&D Deal
DJ
07/11LIGAND PHARMACEUTICALS INC : Other Events (form 8-K)
AQ
07/11LIGAND PHARMACEUTICALS : to Report Second Quarter 2018 Results on August 6th
AQ
07/09LIGAND PHARMACEUTICALS : to Report Second Quarter 2018 Results on August 6th
BU
07/05LIGAND PHARMACEUTICALS : Patent Issued for Derivatives of Uridine 5'-Cyclophosph..
AQ
07/05LIGAND PHARMACEUTICALS : New Immunoglobulins Findings from Ligand Pharmaceutical..
AQ
07/02LIGAND PHARMACEUTICALS : Receives $47 Million from WuXi Biologics for Expansion ..
AQ
06/28LIGAND PHARMACEUTICALS : Patent Issued for Derivatives of Uridine 5'-Cyclophosph..
AQ
06/27LIGAND PHARMACEUTICALS INC : Entry into a Material Definitive Agreement (form 8-..
AQ
06/27LIGAND PHARMACEUTICALS : Receives $47 Million from WuXi Biologics for Expansion ..
BU
More news
News from SeekingAlpha
07/18Cheap Stocks Moving In The Right Direction 
07/17Playing The Expectations Game In Biotech 
07/11Ligand Pharma teams up with J&J to develop transgenic chicken platform 
07/09BY THE NUMBERS : Growth Leaders With Rising Earnings Expectations 
07/01WEEK IN REVIEW : CStone Acquires China Rights To Leukemia Drug In $424 Million D.. 
Financials ($)
Sales 2018 217 M
EBIT 2018 149 M
Net income 2018 116 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 46,76
P/E ratio 2019 66,55
Capi. / Sales 2018 21,8x
Capi. / Sales 2019 23,3x
Capitalization 4 724 M
Chart LIGAND PHARMACEUTICALS INC
Duration : Period :
Ligand Pharmaceuticals Inc Technical Analysis Chart | LGND | US53220K5048 | 4-Traders
Technical analysis trends LIGAND PHARMACEUTICALS INC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 205 $
Spread / Average Target -7,7%
EPS Revisions
Managers
NameTitle
John L. Higgins Chief Executive Officer & Director
Matthew W. Foehr President & Chief Operating Officer
John W. Kozarich Chairman
Matthew E. Korenberg CFO, Principal Accounting Officer & EVP-Finance
Vincent Antle Senior VP-Technical Operations & Quality Assurance
Sector and Competitors
1st jan.Capitalization (M$)
LIGAND PHARMACEUTICALS INC.61.94%4 724
CELLTRION, INC.--.--%32 830
IQVIA HOLDINGS INC11.34%22 488
LONZA GROUP9.38%21 400
INCYTE CORPORATION-25.97%14 887
SEATTLE GENETICS, INC.28.95%10 750